# DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease

Study · id `cardio:ct-nct04218656` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04218656](<https://clinicaltrials.gov/study/NCT04218656>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04218656

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT04218656. Non-randomized; no masking; primary purpose treatment. Start 2020-06-08 (actual); primary completion 2021-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT04218656, source copy `cardio:ctgov-nct04218656-2022-01-14`, retrieved 2026-10-31)
- Started: 2020-06-08 (actual) (ClinicalTrials.gov record NCT04218656, source copy `cardio:ctgov-nct04218656-2022-01-14`, retrieved 2026-10-31)
- Primary completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT04218656, source copy `cardio:ctgov-nct04218656-2022-01-14`, retrieved 2026-10-31)
- Completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT04218656, source copy `cardio:ctgov-nct04218656-2022-01-14`, retrieved 2026-10-31)
- Countries: Netherlands (ClinicalTrials.gov record NCT04218656, source copy `cardio:ctgov-nct04218656-2022-01-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04218656-2022-01-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
- Acronym: DUAL-PAD
- Condition: Peripheral Artery Disease
- Intervention (Drug): Rivaroxaban 2.5 Mg Oral Tablet
- Lead sponsor: Radboud University Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Radboud University Medical Center (`cardio:org-radboud-university-medical-center`)

## Provenance

Content hash: 8a9a43d5495735ad852aabb6efc422acb6e60758186315ee3d6933ac28e658a7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
